Re-Configuring Pharma Operations Amid Pandemic Strains
Executive Summary
Senior McKinsey executive shares insights on the potential contours of pharma’s 'reimagined' operations against the backdrop of COVID-19 and striking a balance between supply chain security and the cost component. A dramatic near-term shift to a “completely onshore model” in markets like the US would not realistically be possible, he indicated.
You may also be interested in...
McKinsey Exec On Generative AI in R&D And Pharmacovigilance, Digital Twins
McKinsey & Company's senior partner Vikas Bhadoria, in this first instalment of a wide-ranging two-part interview with Scrip, outlines a number of use cases to define where pharma currently is and the potential value that can be unlocked as industry adopts new technologies such as generative AI, digital twins and the metaverse.
Indian ‘Lighthouses’ Deliver Gains Amid Price Erosion, Rising Input Costs
Senior executives from Dr Reddy’s and Cipla showcase the “step-change” in performance across cost, quality and delivery metrics at their ‘lighthouse’ manufacturing sites in India as industry tackles dwindling operating margins and evolving compliance requirements.
When You Can’t Win For Losing: Kodak And The Reshoring Of US Pharmaceutical Manufacturing
Kodak, Fujifilm and startups Civica Rx and Phlow fight with grit, vision and government support to restore US pharmaceutical manufacturing.